Frank J Criado MD FACS FSVM

By Frank J Criado, MD, FACS, FSVMI couldn’t help but take notice of a recent guidance document drafted by the UK National Institute for Health and Care Excellence (NICE) recommending rivaroxaban (Xarelto, Bayer Healthcare) as a clinically effective and cost-effective option for treating pulmonary embolism and preventing recurrent deep vein thrombosis and pulmonary embolism after acute pulmonary embolism in adults. | Read More

By Frank J Criado, MD, FACS, FSVMMicari et al. published important clinical data in the March 2013 issue of the Journal of the American College of Cardiology (JACC 2013;6:282-89) related to the performance of femoropliteal angioplasty using drug-eluting balloon technology. This was a non-industry sponsored independent, prospective, multicenter registry purported to assess clinical outcomes of femoropopliteal angioplasty with a paclitaxel-eluting balloon (PEB) (In.Pact Admiral, Medtronic, Inc., Minneapolis, MN). | Read More

By Frank J. Criado, MD, FACS, FSVMOut of several important updates and new data presented at the recent ISET 2013 25th anniversary conference, a talk by Jeff Olin, DO (Director of Vascular Medicine at Mount Sinai in New York) on critical limb ischemia (CLI) and peripheral arterial disease (PAD) caught my eye. And it is clearly worth it of further dissemination because it may not be widely known or understood, at least not yet. | Read More